Sinopharm COVID-19 booster weaker against Omicron 鈥� study
FILE PHOTO: A logo of Sinopharm is pictured during a government-organized visit to the production line of COVID-19 vaccine by Beijing Institute of Biological Products of Sinopharm’s China National Biotec Group (CNBG), in Beijing, China February 26, 2021. REUTERS/Tingshu Wang
BEIJING — A COVID-19 booster shot produced by China’s Sinopharm had “significantly lower” neutralizing activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine’s efficacy against Omicron remained unclear.
The study – conducted by researchers from Shanghai Jiao Tong University and a Shanghai-based lab specializing in respiratory infectious diseases – compared the activity of Sinopharm’s booster vaccine against an older coronavirus strain from Wuhan.
The neutralizing antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction, compared with its activity against a Wuhan strain, according to the paper published on Saturday.
Sinopharm did not immediately respond to a request for comment.
Sinopharm’s BBIBP-CorV vaccine and Sinovac Biotech’s CoronaVac are the two most used vaccines in China and are the leading COVID-19 vaccines exported by the country. Sinopharm also has a second vaccine in use in China.
Article continues after this advertisementThe study analyzed samples from 292 healthcare workers who received a third dose, or booster shot, about eight to nine months after their second dose. After a further four weeks, serum samples from 78.1% participants retained neutralizing activity against Omicron, researchers said in a paper that has not been peer reviewed.
Article continues after this advertisementHowever, the study authors cautioned the results were not equal to how well a Sinopharm booster could shield recipients from diseases caused by Omicron, as neutralization is only part of the human immune response.
The testing against the earlier Wuhan strain showed that about eight to nine months after the second BBIBP-CorV shot, the neutralizing activity “could hardly be detected”, while the booster lifted the response significantly, according to the paper.
